FOX Translator
No data currently available.
No data currently available.
You know that buying a stock makes you part owner of a company, theoretically with millions of other people. But, while ownership has its privileges (at minimum you get a neat stock certificate and an invitation to the annual meeting), being an owner doesn't necessarily pay. Sure, you make money if the stock goes up, but only if you sell, and you can, in theory, lose all the value of your investment if the stock tanks.
Enter the dividend. Here, you get money simply from holding the stock. Companies pay a yield, which is expressed in a percentage based on the stock's price. For example, if a stock trades at $10, and pays a 10% annual yield, your dividend payment would be a $1. (Usually, companies break out the payments quarterly, so, using our example, you¿d get, well, a quarter each quarter.)
Companies that pay dividends fall into a few categories. First, you've got your big, stable companies that generate enough cash that it makes sense to throw some back to shareholders. Next, there are businesses, like real estate investment trusts, that are in the business of sitting back and receiving cash, then distributing it to holders. And, then there are companies that need to dangle a high dividend yield like a carrot to ease investor fears. Cigarette-maker Altria has been doing this for years.
Simply because a company pays a dividend doesn't make it a good investment. After all, you may want to take a chance on a growth stock that can move higher in price than dividend payers are known to do. But, you can¿t beat the safety of knowing that, even if a stock doesn't move in a year, you¿re at least making something off your investment.
Home / Markets / Industries / Health Care
Monday, June 30, 2008
Crystalens HD(TM) Receives FDA Approval
Comtex
ALISO VIEJO, Calif., Jun 30, 2008 (BUSINESS WIRE) ----Bausch & Lomb announced today that it has received approval from the Food and Drug Administration (FDA) to market the Crystalens HD(TM) in the United States. Crystalens accommodating intraocular lens (IOL) was first approved by the FDA in November 2003. The Crystalens HD is the fourth generation of the only FDA approved accommodating lens.
The surface of the Crystalens HD has been shaped to enhance the depth of focus with a proprietary optical modification. The enhanced optic provides an increased depth of focus which is designed to improve near vision without compromising intermediate or distance vision. The HD lens does this without inducing increased undesirable dysphotopsia or night vision symptoms.
A total of 125 primary eyes were implanted with the Crystalens HD in patients who had a visually significant cataract, less than 1 diopter of corneal astigmatism, and the potential for best corrected visual acuity (BCVA) of 20/25 or better in both eyes. Of these patients, 80% reported vision at J2 or better at four (4) months.
"Extensive market research has clearly indicated that patients and surgeons alike are asking for a truly accommodating IOL as their choice of lens. With these results, where patients reported getting one more line of near vision, we are coming ever closer to meeting the desired need for an optic that does provide truly good near vision without compromising the quality of vision at intermediate or distance," said Michael Judy, vice president of global marketing - Surgical.
Dr. John Hovanesian was a Principal Investigator in the FDA study. Dr. Hovanesian serves as Clinical Instructor at the Jules Stein Eye Institute, UCLA in California and is in private practice at Harvard Eye Associates in Laguna Hills, California.
"If I were a patient having cataract surgery, I would want an IOL that projects a single point of focus and also provides a broad range of distance, intermediate and near vision. The Crystalens HD is the best available lens to achieve that goal," said Dr. Hovanesian. "There is no question that the HD will be my lens of choice for presbyopia correction in patients with cataracts."
Bausch & Lomb officials said that surgeons will be instructed to continue to use the same surgical protocols for the Crystalens HD as they have used in the past. The Company has said that it will begin shipping the Crystalens HD the week of July 7th.
ABOUT CRYSTALENS HD
Crystalens HD is a product developed by Bausch & Lomb. To learn more about Crystalens HD, please visit www.crystalens.com. The Crystalens(R) Call Center is 1-888-393-6642.
ABOUT BAUSCH & LOMB
Bausch & Lomb is an eye health company dedicated to perfecting vision and enhancing life. Bausch & Lomb offers the world's most comprehensive portfolio of eye health products. The Company has one of the oldest, best known and most respected healthcare brands in the world. Bausch & Lomb offers a full suite of products in cataract and vitreoretinal surgery including intraocular lenses and delivery systems, phacomulsification equipment and other surgical instruments and devices. To learn more about Bausch & Lomb, visit www.bausch.com
SOURCE: Bausch & Lomb
News Media: Mike McDougall, APR 585-338-5469 mmcdougall@bausch.com
Copyright Business Wire 2008 ********************************************************************** As of Thursday, 06-26-2008 23:59, the latest Comtex SmarTrend� Alert, an automated pattern recognition system, indicated a DOWNTREND on 07-17-2007 for BOL @ $67.60. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright � 2004-2008 Comtex News Network, Inc. All rights reserved.
Market Snapshot
| Symbol | Last Price | Netchange | Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
